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two-week recall. Two measures were derived for each
condition—hours/worker/week of lost productive time
(LPT) and its dollar equivalent. Several derivation
methods were considered. We selected a conservative
method based on self-reported attribution for LPT. A
random sample of 13,252 workers 18–65 years of age
completed the WHI between July 2, 2001 and January 2,
2002. LPT was converted to dollars/worker/week using
self-reported annual salary. Tailored employer-speciﬁc
reports can be generated based on the characteristics of
an employer’s workforce including age, gender, occupa-
tion, and region. The illustration follows.
RESULTS: Company Y (n = 5,400) included 3,460 men
and 1,940 women with similar age distributions: 45%
18–34 years, 30% 35 to 44 years, 20% 45 to 54 years,
and 5% 55+ years. The ﬁve episodic/chronic-episodic
health conditions associated with the most LPT in
Company Y were cold/ﬂu (8.2%), headache (5.9%), low
energy (3.2%), back pain (3.1%), and digestive disorders
(2.8%). LPT attributed to each condition among those
affected was cold/ﬂu (0.42), headache (0.22), back pain
(0.21), low energy (0.14), and digestive disorders (0.12).
These ﬁve conditions potentially cost the employer an
estimated $5.1 million dollars/year in LPT.
CONCLUSIONS: The APA can be used to generate 
tailored reports for employers of health-related work 
loss. This is a ﬁrst step toward providing employers with
concrete estimates of the indirect cost of speciﬁc health
conditions.
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The cost of drug-related morbidity and mortality is stag-
gering, estimated to be $177 billion USD annually in the
United States. Much of this is preventable and occurs in
older adults.
OBJECTIVES: Given the lack of a Canadian cost-of-
illness model, our objective was to determine the eco-
nomic impact of preventable drug-related morbidity
(PDRM) in older adults in Canada from a public payer
perspective.
METHODS: A probability pathway model was devel-
oped for PDRM in older adults, based on a previously
published methodology. To determine the probabilities
that would be assigned to each branch of the pathway, a
panel of 25 health care professionals (12 general practi-
tioners, 4 clinical pharmacologists, 6 geriatricians, and 3
pharmacists) completed a written survey. Data from the
Population Health Research Unit (PHRU) at Dalhousie
University was primarily used to determine the costs that
were assigned to each outcome. Data analysis was con-
ducted by using Treeage (DATA,v3.5).
RESULTS: The cost-of-illness model estimated that the
annual cost of PDRM in older adults in Canada is $10.9
billion CAN. Admissions to long-term care were found
to be the biggest driver in the model, accounting for $6.7
billion CAN of the costs. One-way sensitivity analyses
were performed, varying the probability and cost esti-
mates, but the estimated total cost was relatively insensi-
tive to these changes.
CONCLUSIONS: The burden of PDRM is potentially
substantial in both the adverse clinical outcomes to the
patient and the economic impact to our health care
system. At an estimated annual cost of $10.9 billion,
PDRM in older adults is one of the more costly “illnesses”
in Canada, with a greater annual cost than either cancer
or respiratory diseases. This study represents a pro-
gression in the literature on cost-of-illness models by
focusing exclusively on (1) preventable drug-related mor-
bidities that (2) occur in older adults, in (3) Canada.
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OBJECTIVES: Quantify the prevalence and magnitude 
of utilization of pharmacy beneﬁts in a public employees
indemnity insurance program.
METHODS: The study was a retrospective study of paid
pharmacy claims for an insured population of approxi-
mately 150,000 eligible members per month for ﬁve ﬁscal
years from July 1996 to June 2001. Eligibility and paid
pharmacy claims ﬁles were analyzed to determine the 
proportion of members who were recipients, intensity
(number of prescriptions) per recipient per year, phar-
macy reimbursement per prescription, and pharmacy
reimbursement cost per member per month. The data
were divided into twenty age groups and a sub-analysis
was performed to assess changes in proportion, intensity,
and pharmacy reimbursement for each age group over a
ﬁve-year period.
RESULTS: Over the ﬁve-year period, the proportion of
recipients to eligible increased 9.4% from 0.717 to 0.784;
intensity per recipient increased 13.9% from 16.5 to 
18.8 prescriptions per recipient per year; pharmacy reim-
bursement per prescription increased 51.2% from $40.17
to $60.74 per member per month. This led to an overall
increased cost per member per month over the ﬁve-year
period of 83.2% ($42.20 to $77.31). Intensity per recip-
ient and proportion of recipients increased greatly with
age. Recipients aged 10–14 received 5.8 prescriptions per
year while those aged 30–34 received 9.4, those aged
50–54 received 18.9, and those aged 70–74 received 30.1
prescriptions per year in ﬁscal year 2001. The proportion
of recipients to eligible increased from 0.593 to 0.730 to
0.834 to 0.946, respectively, for the age groups per the
ﬁscal year.
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CONCLUSION: Managerial strategies can be developed
to control some of the increasing costs by promoting the
use of cost-effective therapies for optimum outcomes but
pharmacy beneﬁt costs will continue to escalate because
of an increasing proportion of recipients and intensity per
recipients and compounded by an aging population.
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OBJECTIVES: The American Productivity Audit (APA),
an on-going week-to-week telephone survey, provides
valid and reliable estimates of health-related lost produc-
tive work time. This paper describes the APA and identi-
ﬁes the ﬁve most costly episodic/chronic-episodic health
conditions.
METHODS: We developed and validated the Work 
and Health Interview (WHI) for APA administration. The
WHI quantiﬁes missed work hours and lost produc-
tive time while at work for speciﬁc health conditions
using two-week recall. Two measures were derived for
each condition—hours/worker/week of lost productive
time (LPT) and its dollar equivalent. Several derivation
methods were considered. We selected a conservative
method based on self-reported attribution for LPT. A
random sample of 13,252 workers 18–65 years of age,
selected using Random-Digit-Dialing, completed the 
WHI by phone in their homes between July 2, 2001 and
January 2, 2002. LPT was converted to dollars/worker/
week using self-reported annual salary.
RESULTS: Among all respondents, mean LPT from
episodic/chronic-episodic conditions was 1.6 hours/
worker/week (1.8 hours/week for women; 1.4 hours/week
for men). Thirty-three percent reported LPT from >1 of
16 different episodic/chronic-episodic conditions. The
prevalence of the ﬁve conditions associated with the most
LPT/worker/week was cold/ﬂu (8.9%), headache (7.3%)
back pain (3.9%), low energy (3.7%), and arthritis
(2.7%). LPT attributed to each condition among those
affected was cold/ﬂu (0.43), headache (0.23), back pain
(0.20), low energy (0.14), and arthritis (0.13). Extrapo-
lating to the US workforce, the estimated cost of these
ﬁve health conditions to employers was approximately
$124.7 billion/year.
CONCLUSIONS: The APA provides national estimates
of health-related LPT. Results indicate that common con-
ditions like cold/ﬂu, headache, and back pain result in a
signiﬁcant but largely invisible ﬁnancial loss to employ-
ers. Findings may be subject to seasonality bias based on
only six months of data collection. Unbiased estimates
that we will benchmark to the Current Population Survey
will follow as we collect additional data.
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OBJECTIVE: To examine the CE of adding minipool
NAT to current blood screening (CS) of volunteer blood
donations to reduce the risk of HBV, HCV and HIV infec-
tion in the United States.
METHODS: We developed a decision analytic model 
of screening volunteer blood donations in the US based
on recently published Markov models of HBV, HCV, and
HIV infection to estimate discounted lifetime costs and
quality-adjusted life year (QALY) gains. Infection risk
(including prevalence and the window period between
antigen and antibody detectability in the donated blood),
and test sensitivities were derived from the literature. 
Age-speciﬁc ten-year survival of transfusion recipients
was from Vamvakas (1994) and the age distribution 
from a private managed care database for transfusions in
1995. Secondary analyses considered alternative screen-
ing strategies.
RESULTS: The model estimated NAT would annually
prevent 37, 128 and 7 transfusion-acquired cases of HBV,
HCV, and HIV respectively compared to CS alone (6.2
million transfusion recipients). HCV had the greatest
impact on total QALYs and costs. Although the cost per
case of HIV avoided was 3–4 times that for HBV or HCV,
the overall impact of HIV on CE was small. Adding NAT
to CS would add 86 life years, at an incremental cost per
life year gained of $2.1M and an incremental cost per
QALY gained of $1.2M. The CS + NAT-p24 strategy
dominated CS + NAT, and had an incremental cost per
QALY of $0.9M compared to CS. Results were most sen-
sitive to disease incidence rates, screening test costs, esti-
mates of window period closure, and the age distribution
of transfusion recipients.
CONCLUSIONS: The CE of adding NAT to current
screening, although not within a range considered cost-
effective for health care treatments, may be reasonable
when considered in the context of other blood-related
preventive interventions such as autologous blood 
donation, and the desire for a zero tolerance level for
infections from blood transfusions.
